March has seen a slew of executive hires, exits and layoffs across the healthcare industry. For example, providers like Providence and Geisinger have appointed new C-suite leaders, and companies like ...

President Donald Trump’s administration recently cancelled billions of dollars in funding to the National Institutes of Health (NIH), causing widespread concern among researchers and tech ...

About 90% of healthcare organizations are insecurely connected to the internet and running systems vulnerable to exploitation ...

A month before 23andMe’s bankruptcy filing, CEO Anne Wojcicki had a fully financed proposal to take the genetic testing ...

Novo Nordisk has been on the hunt for differentiated obesity drugs that could complement its blockbuster GLP-1 agonist, Wegovy. It’s found a contender with preclinical data indicating it can ...

Obesity has many drivers, but for those with a particular rare metabolic disorder, the root cause is genetic. These patients develop ravenous hunger unsatisfied by any amount of food. The constant ...

For the first time, traditional drug spending has exceeded specialty drug spending, largely due to the demand for GLP-1s, according to a new report from Evernorth Research Institute. Evernorth ...

Welcome back to another episode of MedCity FemFwd, a podcast dedicated to discussing the breakthroughs and challenges in women’s health. In this episode, we’re joined by Dr. Audrey Jiricko ...

The daily schedules of healthcare professionals (HCPs) are busy, leaving little time to spend searching for information on medicines. Like all areas of modern life, HCPs are turning to online ...

Chronic back pain is one of the world’s most underrated and underestimated health issues. It is the leading cause of disability and work absenteeism globally, creating significant clinical and ...

A GSK pill that offers a lower potential for drug resistance is now FDA approved as a new treatment for a common type of urinary tract infection, the first new oral antibiotic for this indication ...